Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
|Videos|March 16, 2022
Real-world feedback on nasal spray DED treatment
Author(s)Carly Rose, OD, FAAO
Carly Rose, OD, FAAO, shares her experience and patient feedback on implementing the first and only FDA-approved nasal spray for dry eye treatment.
Advertisement
Carly Rose, OD, FAAO, in practice at Eyecare on the Square in Cincinnati, Ohio, shares her experience implementing varenicline solution nasal spray (TYRVAYA, Oyster Point Pharma), the first and only FDA-approved nasal spray for dry eye treatment, in her practice, as well as the promising patient feedback she's received.
Advertisement
Related to this article
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
2
Takeaways from this week in optometry: October 16-23
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5